Study details
Enrolling now
Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs
Massachusetts General Hospital
NCT IDNCT07199335ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
100
Study length
about 1.8 years
Ages
18+
Locations
2 sites in MA
About this study
This trial is testing the use of a long-acting injectable medication called APRETUDE to help prevent HIV infection in adults who inject drugs. The goal is to see if this approach can be used effectively and safely, along with support services, to reduce the risk of HIV transmission among people at high risk.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take APRETUDE (cabotegravir)
PhasePhase 4
Drugcabotegravir
Routeoral
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low7%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
cabotegravir
Drug routes
oral (Oral Tablet)
Body systems
Psychiatry / Mental Health, Immune, Infectious